Cara Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. More Details
Flawless balance sheet with high growth potential.
Share Price & News
How has Cara Therapeutics's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: CARA is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 15% a week.
Volatility Over Time: CARA's weekly volatility has increased from 9% to 15% over the past year.
7 Day Return
1 Year Return
Return vs Industry: CARA underperformed the US Pharmaceuticals industry which returned 15.8% over the past year.
Return vs Market: CARA underperformed the US Market which returned 39% over the past year.
Long-Term Price Volatility Vs. Market
How volatile is Cara Therapeutics's share price compared to the market and industry in the last 5 years?
Simply Wall St News
3 weeks ago | Simply Wall StIt's Unlikely That The CEO Of Cara Therapeutics, Inc. (NASDAQ:CARA) Will See A Huge Pay Rise This Year
1 month ago | Simply Wall StIs Cara Therapeutics, Inc.'s (NASDAQ:CARA) Stock Price Struggling As A Result Of Its Mixed Financials?
2 months ago | Simply Wall StWhat Kind Of Shareholders Hold The Majority In Cara Therapeutics, Inc.'s (NASDAQ:CARA) Shares?
Is Cara Therapeutics undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: CARA ($13.89) is trading below our estimate of fair value ($246.73)
Significantly Below Fair Value: CARA is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: CARA is poor value based on its PE Ratio (47.7x) compared to the US Pharmaceuticals industry average (22.1x).
PE vs Market: CARA is poor value based on its PE Ratio (47.7x) compared to the US market (19.2x).
Price to Earnings Growth Ratio
PEG Ratio: CARA is good value based on its PEG Ratio (0.6x)
Price to Book Ratio
PB vs Industry: CARA is good value based on its PB Ratio (3x) compared to the US Pharmaceuticals industry average (3.2x).
How is Cara Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 8 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: CARA's forecast earnings growth (82.9% per year) is above the savings rate (2%).
Earnings vs Market: CARA's earnings (82.9% per year) are forecast to grow faster than the US market (15.7% per year).
High Growth Earnings: earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: CARA's revenue (49.9% per year) is forecast to grow faster than the US market (9.4% per year).
High Growth Revenue: CARA's revenue (49.9% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if CARA's Return on Equity is forecast to be high in 3 years time
How has Cara Therapeutics performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: CARA has high quality earnings.
Growing Profit Margin: CARA became profitable in the past.
Past Earnings Growth Analysis
Earnings Trend: CARA has become profitable over the past 5 years, growing earnings by -5.6% per year.
Accelerating Growth: CARA has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
Earnings vs Industry: CARA has become profitable in the last year, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (0.6%).
Return on Equity
High ROE: CARA's Return on Equity (6.1%) is considered low.
How is Cara Therapeutics's financial position?
Financial Position Analysis
Short Term Liabilities: CARA's short term assets ($188.4M) exceed its short term liabilities ($16.5M).
Long Term Liabilities: CARA's short term assets ($188.4M) exceed its long term liabilities ($3.3M).
Debt to Equity History and Analysis
Debt Level: CARA is debt free.
Reducing Debt: CARA has not had any debt for past 5 years.
Debt Coverage: CARA has no debt, therefore it does not need to be covered by operating cash flow.
Interest Coverage: CARA has no debt, therefore coverage of interest payments is not a concern.
What is Cara Therapeutics's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate CARA's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate CARA's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if CARA's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if CARA's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of CARA's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Derek Chalmers (56 yo)
Dr. Derek T. Chalmers, Ph.D., D.Sc. co-founded Cara Therapeutics, Inc. in 2004 and has been its Chief Executive Officer and President since September 2004. Dr. Chalmers served as a Principal Investigator a...
CEO Compensation Analysis
Compensation vs Market: Derek's total compensation ($USD2.91M) is about average for companies of similar size in the US market ($USD2.34M).
Compensation vs Earnings: Derek's compensation has been consistent with company performance over the past year.
Experienced Management: CARA's management team is considered experienced (2.6 years average tenure).
Experienced Board: CARA's board of directors are considered experienced (6.9 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 7%.
Cara Therapeutics, Inc.'s company bio, employee growth, exchange listings and data sources
- Name: Cara Therapeutics, Inc.
- Ticker: CARA
- Exchange: NasdaqGM
- Founded: 2004
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$695.222m
- Shares outstanding: 50.05m
- Website: https://www.caratherapeutics.com
Number of Employees
- Cara Therapeutics, Inc.
- 4 Stamford Plaza
- 9th Floor
- United States
Cara Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opi...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/06/23 06:14|
|End of Day Share Price||2021/06/22 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.